The Mayo Clinic Board of Trustees has elected Matthew R. Callstrom, M.D., Ph.D., as the next president and CEO of Mayo Clinic. He will succeed Gianrico Farrugia, M.D., who will remain in the position through December 31, 2026, working closely with Dr. Callstrom to ensure a seamless transition.
Dr. Callstrom is an accomplished physician-scientist and enterprise leader with nearly 25 years of experience at Mayo Clinic. He has held various leadership roles, including medical director for Mayo Clinic Strategy and the AI Program, interim chief strategy officer, and chair of the Department of Radiology at Mayo Clinic in Rochester. He has helped shape Mayo Clinic’s organizational strategy and advance the responsible integration of AI into medicine, including efforts to accelerate the discovery of new cures, detect disease earlier, and give clinicians new capabilities to care for patients with serious and complex conditions.
He is internationally recognized for advancing image-guided cancer treatment, including the development of technologies that more precisely identify and treat cancer. Dr. Callstrom has led and collaborated on numerous clinical trials, resulting in over 200 publications and patents.
Davis, chair of the Mayo Clinic Board of Trustees. “His leadership across patient care, research, strategy, and innovation, combined with his ability to translate scientific discovery and emerging technology into meaningful advances for patients, prepares him exceptionally well to lead Mayo Clinic into its next chapter.”
New Leadership Vision
“I am deeply honored to have the opportunity to lead Mayo Clinic in this moment, serving alongside colleagues whose expertise, curiosity, and commitment to our patients inspire me every day,” says Dr. Callstrom. “Mayo Clinic has always been at its best when we bring the full power of our clinical expertise, science, and innovation to the needs of the patient. Now, we have an opportunity to build on that foundation—accelerating the translation of discovery and emerging technologies into better care and extending Mayo Clinic’s impact to more patients, wherever they are.”
Related Post: Mayo Clinic Biobank aids disease research
Dr. Callstrom is a Minnesota native who earned degrees in chemical engineering and chemistry from the University of Minnesota Twin Cities. He completed a postdoctoral fellowship at Harvard University and earned his medical degree from Mayo Clinic Alix School of Medicine. He went on to complete his residency in diagnostic radiology and fellowship in cross-sectional imaging at Mayo Clinic in Rochester. Dr. Callstrom has been recognized as a Mayo Clinic Distinguished Clinician and served as president of the Society of Interventional Oncology.
Legacy of Progress
Dr. Farrugia has led Mayo Clinic through a period of extraordinary transformation and progress, strengthening the organization and creating momentum for the future. The Board of Trustees is grateful for his continued service and contributions, including significant investments in Mayo Clinic’s people, physical and digital infrastructure, education, research, AI, and new care models, which leave Mayo Clinic well positioned for its next chapter.
“Dr. Callstrom knows Mayo Clinic deeply, understands where healthcare is headed, and has the vision and experience to build on the progress we have made,” says Dr. Farrugia. “I have great confidence in him and in Mayo Clinic’s future.”
Dr. Callstrom will succeed Dr. Farrugia, who has served as president and CEO of Mayo Clinic since 2019. Under Dr. Farrugia’s leadership, Mayo Clinic launched and advanced Bold. Forward., its strategy to transform healthcare by accelerating the discovery, translation, and delivery of more cures for chronic and acute diseases; connecting people with data to create new knowledge and deliver scalable end-to-end solutions; and transforming healthcare by creating its first full, scalable, AI-enabled care transformation platform—Mayo Clinic Platform.